Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01307800 · ClinicalTrials.gov registry record · Phase 3
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3 study, sponsored by Denovo Biopharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 567
- Enrollment target
NCT01307800: Clinical Trial Phase 3 study, sponsored by Denovo Biopharma.
NCT01307800 is a Phase 3 study that was terminated before completion, run by Denovo Biopharma. The registered enrollment target is 567 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01307800, a Phase 3 study, was terminated before completion, sponsored by Denovo Biopharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 567 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether at least 1 dose level of LY2140023 given to acutely ill patients with schizophrenia will demonstrate significantly greater efficacy as compared to placebo.
Primary Outcome
The PANSS scale assessed participants (pts) for positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. The scale consisted of 30 items. Each item was rated from 1 (absence of symptoms) to 7 (symptoms extremely severe). The sum of the 30 items was defined as the PANSS total score and ranged from 30 to 210. The least squares (LS) mean was estimated using a mixed-effects model with repeated measures (MMRM) that included the fixed, categorical e
Interventions
- DRUG Placebo
- DRUG LY2140023
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 567 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
Why NCT01307800 stopped before completion
NCT01307800 is an interventional study that assigns participants to a tested intervention. The registered 567 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01307800 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01307800 about?
NCT01307800 is a clinical study titled "A Study of LY2140023 in Patients With Schizophrenia". The purpose of this study is to determine whether at least 1 dose level of LY2140023 given to acutely ill patients with schizophrenia will demonstrate significantly greater efficacy as compared to placebo.
What is the current status of trial NCT01307800?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 567 participants. The study started on 2011-03. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01307800?
The interventions under investigation include: Placebo (DRUG), LY2140023 (DRUG).
Who is sponsoring clinical trial NCT01307800?
This trial is sponsored by Denovo Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01307800's enrollment target sits among peer trials
567 667th of 2000 higher than 1,334 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05472441 · 568 participants · NA
Linking Education, Produce Provision, and Community Referrals to Improve Diabetes Care (LINK)
- NCT05000645 · 570 participants · NA
Grocery Delivery and Healthy Weight Gain Among Low-income Pregnant Young Women
- NCT06239844 · 570 participants · NA
Navigating Together for Equitable Asthma Management for Children in Families Who Communicate in Language Other Than English
- NCT06701903 · 570 participants · Phase 2
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia